Millipore Sigma Vibrant Logo

504377 AMPK Signaling Activator XIII, ZLN005 - CAS 4529-96-8 - Calbiochem

504377
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₁₇H₁₈N₂ 4529-96-8

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.04377.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 25 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable benzimidazole that, in addition to its inhibitory potency against luciferase activity (IC50 <10 nM), also activates AMPK signaling by increasing cellular ADP/ATP ratio via mitochondria respiration upcoupling, effectively activating AMPK & PGC-1α in muscle, but not liver, cell types both in cultures (5-20 µM in rat L6 myotubes) in vitro and in db/db mice (15 mg/kg/day via p.o.) in vivo. Reported to improve glucose and insulin tolerance of db/db mice without any apparent effects on body weight or food intake.
      Catalogue Number504377
      Brand Family Calbiochem®
      SynonymsLuciferase Inhibitor IV, 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazole, 2-(4-(2-Methyl-2-propanyl)phenyl)-1H-benzimidazole
      References
      ReferencesZhang, L.N., et al. 2013. Diabetes. 62, 1297.
      Product Information
      CAS number4529-96-8
      FormPinkish-white powder
      Hill FormulaC₁₇H₁₈N₂
      Chemical formulaC₁₇H₁₈N₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationCalbiochem AMPK Activator, CAS 4529-96-8, inhibits luciferase activity, and activates AMPK signaling.
      Biological Information
      Primary Targetincreases cellular ADP/ATP ratio via mitochondria respiration uncoupling
      Secondary targetluciferase activity inhibitor
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      AMPK Signaling Activator XIII, ZLN005 - CAS 4529-96-8 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Zhang, L.N., et al. 2013. Diabetes. 62, 1297.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision20-September-2013 JSW
      SynonymsLuciferase Inhibitor IV, 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazole, 2-(4-(2-Methyl-2-propanyl)phenyl)-1H-benzimidazole
      DescriptionA cell-permeable benzimidazole that, in addition to its inhibitory potency against luciferase activity (IC50 <10 nM), is reported to activate AMPK signaling by increasing cellular ADP/ATP ratio via mitochondria respiration uncoupling in a cell type-specific manner, effectively activating AMPK & PGC-1α in muscle, but not liver, cell types both in cultures (5-20 µM & 1-24 h in rat L6 myotubes; no effect in primary rat hepatocytes) in vitro and in db/db mice (gastrocnemius/calf muscle, but not liver tissue; 15 mg/kg/day via p.o. for 6 wks) in vivo. ZLN005 is orally available in mice (plasma Cmax & Tmax = 3.7 µM & 15 min, respectively, following single 15 mg/kg oral dosage to db/db mice) and is efficacious in improving glucose (1.5 g/kg i.p.) tolerance among 4-wk-treated and insulin (1 unit/kg) tolerance among 5-wk treated db/db mice (by 14% and 18%, respectively; 15 mg/kg/day via p.o.) in vivo without any apparent effects on body weight or food intake among db/db or non-diabetic controls.
      FormPinkish-white powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number4529-96-8
      Chemical formulaC₁₇H₁₈N₂
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesZhang, L.N., et al. 2013. Diabetes. 62, 1297.